ITGR:NYSEInteger Holdings Corporation Analysis
Data as of 2026-04-11 - not real-time
$85.11
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Better-than-expected Q4 2025 results propelled Integer Holdings (ITGR) up ~3.4% intraday, but the stock now trades at $85.11, still below its 20‑day and 50‑day SMAs (≈$85.72 and $85.74), signaling short‑term bearish momentum. The price sits comfortably above the technical support at $81.99 and well under the resistance near $89.07. RSI at 48 indicates a neutral stance, while the MACD histogram is slightly negative, reinforcing a cautious outlook. Revenue grew 5% YoY to $1.85 B, yet profit margins are thin at 5.5% and ROE is only 6.1%. The balance sheet is leveraged, with $1.32 B of debt versus $17 M cash, yielding a debt‑to‑equity of 75%. Despite the leverage, the forward P/E of 11.8 and analyst median target of $93.5 suggest roughly 10% upside.
The industry average P/E of 25.9 makes the current trailing P/E of 29.4 appear expensive, but the forward earnings compression narrows the gap. Beta of 0.67 and a 30‑day volatility of 27% point to modest systematic risk but heightened price swings. Volume trends are decreasing, which could limit short‑term liquidity. The “Extreme Greed” sentiment index (87) reflects strong market optimism, yet the max drawdown of 50% warns of downside potential. With no dividend, income‑focused investors have limited appeal. Overall, the stock balances a bullish earnings narrative against a leveraged balance sheet and mixed technical signals, requiring investors to weigh near‑term upside from earnings momentum against longer‑term debt burden and modest growth.
The industry average P/E of 25.9 makes the current trailing P/E of 29.4 appear expensive, but the forward earnings compression narrows the gap. Beta of 0.67 and a 30‑day volatility of 27% point to modest systematic risk but heightened price swings. Volume trends are decreasing, which could limit short‑term liquidity. The “Extreme Greed” sentiment index (87) reflects strong market optimism, yet the max drawdown of 50% warns of downside potential. With no dividend, income‑focused investors have limited appeal. Overall, the stock balances a bullish earnings narrative against a leveraged balance sheet and mixed technical signals, requiring investors to weigh near‑term upside from earnings momentum against longer‑term debt burden and modest growth.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Positive earnings surprise and upward earnings forecast
- Price near technical support with modest upside to resistance
- Forward P/E compression indicating valuation upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst median price target of $93.5 (~10% upside)
- Improving forward earnings outlook
- Industry positioning in high‑growth medical device segments
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High debt‑to‑equity ratio and limited cash cushion
- Modest profit margins and ROE
- Regulatory and reimbursement uncertainties in the medical‑device sector
Key Metrics & Analysis
Financial Health
Revenue Growth5.00%
Profit Margin5.55%
P/E Ratio29.4
ROE6.11%
ROA4.75%
Debt/Equity75.44
P/B Ratio1.7
Op. Cash Flow$196.1M
Free Cash Flow$76.9M
Industry P/E26.0
Technical Analysis
TrendBearish
RSI47.9
Support$81.99
Resistance$89.07
MA 20$85.72
MA 50$85.74
MA 200$91.74
MACDBearish
VolumeDecreasing
Fear & Greed Index87.09
Valuation
Target Price$93.25
Upside/Downside9.56%
GradeFair
TypeBlend
Risk Assessment
Beta0.67
Volatility27.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.